CD8A and breast cancer: Another limitation of this study, which obstructed our attempt to assess the impact of the TIL subset on patient survival according to BC molecular subtypes, was the small number of events of interest in the category of patients with high counts/mm2 of sCD8, iCD8, and total CD8.